| Literature DB >> 28413399 |
Jacqueline Le Goaster1, Patrice Bouree1, Franck N El Sissy2, Florence Phuong Bui2, Johanna Pokossy Epee2, Paul Rollin2, Frédéric Tangy3, Anne-Lise Haenni4.
Abstract
INTRODUCTION: At the onset of the 20th century, ancient clinical observations of cancer epidemics in Bantu populations of Sub-Saharan Africa were discovered. They were reported from 1914 to 1960, but remained unexplained. In 1983, in San Francisco, Calif., USA, cancer epidemics were related to infections by the human immunodeficiency virus type 1 (HIV-1) known as AIDS disease. Yet since 1996, it is known that HIV-1 strains are not the only ones involved. In Sub-Saharan Africa, recurrent orobuccal herpes simplex virus type 1 (HSV-1) and genital recurrent herpes simplex virus type 2 (HSV-2) appeared many times prior to infection by HIV-1. CASE REPORTS: Data on these ancient medical observations regarding African cancer epidemics can today be referred to as the relationship between the unfortunate immune deficiency of herpes in Bantu populations and HIV-1 viral strains. For centuries, the Bantu populations dispersed in forests were living in close proximity to chimpanzees infected by simian immunodeficiency virus (SIV) and were exposed to SIV contamination which became HIV-1 in human beings. Presently, these unexplained Bantu cancer epidemics can be linked to the viral partnership of HSV-1/HSV-2 to HIV-1 strains.Entities:
Keywords: Bantu populations; HIV-1 prevention; HSV-1/HSV-2/HHV3 infections; Herpesviruses; Sub-Saharan Africa
Year: 2016 PMID: 28413399 PMCID: PMC5385453 DOI: 10.1159/000450939
Source DB: PubMed Journal: Case Rep Oncol ISSN: 1662-6575
Fig. 1Kaposi's sarcomas in tropical Africa. Correlation between Kaposi's sarcomas and Bantu ethnicities in Africa. Adapted from Oettle [1].
Summary of the known human pathogenic herpesviruses
| HSV-1 | Oro-buccal herpes |
| HSV-2 | Genital herpes |
| VZV, HHV-3 | Varicella zoster virus: HHV-3; the serodiagnostic level is the first step in establishing the basis of the herpesvirus immunogenetic defense during childhood in all humans; during life, it can favor or not the immune ability when facing other pathogenic herpesviruses; the efficiency of the anti-HHV-3 vaccine against HSV-1/HSV-2 recurrences was observed [ |
| HHV-4 | Epstein-Barr virus: mononucleosis, Hodgkin lymphoma |
| HHV-5 | Cytomegalovirus = CMV, spontaneous abortion |
| HHV-6 | Roseolovirus = Hashimoto thyroiditis, Pityriasis rosea and numerous other abnormalities |
| HHV-8 | Kaposi's sarcoma |
Data on Kaposi's sarcomas presented at the Symposium held in Kampala, Uganda, 1961
| Region | Country (year) | All cancers, n | Kaposi's sarcomas, n (%) | Lymphomas, n (%) |
|---|---|---|---|---|
| North Africa | Tunisia (1960) | 281 | 1 (0.04) | 0 (0.00) |
| West Tropical Africa | Senegal, Mali (1954) | 4,077 | 39 (0.95) | 386 (9.47) |
| Central Tropical Africa | Belgian Congo (1957) | 2,623 | 242 (9.20) | 330 (12.60) |
| East Tropical Africa | Tanzania (1960) | 3,006 | 145 (4.80) | 242 (8.00) |
| South Africa | Transvaal (1951) | 3,323 | 46 (1.40) | 177 (5.30) |
Kaposi's sarcomas and lymphomas in Africa (1914–1960). Percentage of all cancers in histopathological series among Black populations in both sexes, following the report by Findlay [21].
Fig. 2Prevalence of Kaposi's sarcoma and lymphoma epidemics (1914–1960). Modified from Oettle [1]. Percentage of all cancers among Black African populations in both sexes, following the report by Findlay [21].
Fig. 3Percentage of Kaposi's sarcoma and lymphoma epidemics among all cancers in males from 1988 to 1997 in Gambia, compared to the USA where at that time these cancers were related to AIDS diseases. Modified from Bah et al. [22].